Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Initial Characterization of the Epstein⁻Barr Virus BSRF1 Gene Product.

Yanagi Y, Masud HMAA, Watanabe T, Sato Y, Goshima F, Kimura H, Murata T.

Viruses. 2019 Mar 21;11(3). pii: E285. doi: 10.3390/v11030285.

2.

The BOLF1 gene is necessary for effective Epstein-Barr viral infectivity.

Masud HMAA, Watanabe T, Sato Y, Goshima F, Kimura H, Murata T.

Virology. 2019 May;531:114-125. doi: 10.1016/j.virol.2019.02.015. Epub 2019 Feb 23.

PMID:
30856483
3.

Publisher Correction: Defective Epstein-Barr virus in chronic active infection and haematological malignancy.

Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, Inoue M, Kawa K, Seto M, Ohshima K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Narita Y, Yoshida M, Goshima F, Kawada JI, Nishida T, Kiyoi H, Kato S, Nakamura S, Morishima S, Yoshikawa T, Fujiwara S, Shimizu N, Isobe Y, Noguchi M, Kikuta A, Iwatsuki K, Takahashi Y, Kojima S, Ogawa S, Kimura H.

Nat Microbiol. 2019 Mar;4(3):544. doi: 10.1038/s41564-019-0387-8.

PMID:
30705423
4.

S-Like-Phase Cyclin-Dependent Kinases Stabilize the Epstein-Barr Virus BDLF4 Protein To Temporally Control Late Gene Transcription.

Sato Y, Watanabe T, Suzuki C, Abe Y, Masud HMAA, Inagaki T, Yoshida M, Suzuki T, Goshima F, Adachi J, Tomonaga T, Murata T, Kimura H.

J Virol. 2019 Apr 3;93(8). pii: e01707-18. doi: 10.1128/JVI.01707-18. Print 2019 Apr 15.

PMID:
30700607
5.

Defective Epstein-Barr virus in chronic active infection and haematological malignancy.

Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, Inoue M, Kawa K, Seto M, Ohshima K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Narita Y, Yoshida M, Goshima F, Kawada JI, Nishida T, Kiyoi H, Kato S, Nakamura S, Morishima S, Yoshikawa T, Fujiwara S, Shimizu N, Isobe Y, Noguchi M, Kikuta A, Iwatsuki K, Takahashi Y, Kojima S, Ogawa S, Kimura H.

Nat Microbiol. 2019 Mar;4(3):404-413. doi: 10.1038/s41564-018-0334-0. Epub 2019 Jan 21. Erratum in: Nat Microbiol. 2019 Jan 30;:.

PMID:
30664667
6.

Regulation of Epstein-Barr Virus Life Cycle and Cell Proliferation by Histone H3K27 Methyltransferase EZH2 in Akata Cells.

Ichikawa T, Okuno Y, Sato Y, Goshima F, Yoshiyama H, Kanda T, Kimura H, Murata T.

mSphere. 2018 Nov 28;3(6). pii: e00478-18. doi: 10.1128/mSphere.00478-18.

7.

Oncolytic Virotherapy by HSV.

Watanabe D, Goshima F.

Adv Exp Med Biol. 2018;1045:63-84. doi: 10.1007/978-981-10-7230-7_4. Review.

PMID:
29896663
8.

Characterization of a Suppressive Cis-acting Element in the Epstein-Barr Virus LMP1 Promoter.

Yoshida M, Murata T, Ashio K, Narita Y, Watanabe T, Masud HMAA, Sato Y, Goshima F, Kimura H.

Front Microbiol. 2017 Nov 22;8:2302. doi: 10.3389/fmicb.2017.02302. eCollection 2017.

9.

Epstein-Barr Virus BKRF4 Gene Product Is Required for Efficient Progeny Production.

Masud HMAA, Watanabe T, Yoshida M, Sato Y, Goshima F, Kimura H, Murata T.

J Virol. 2017 Nov 14;91(23). pii: e00975-17. doi: 10.1128/JVI.00975-17. Print 2017 Dec 1.

10.

The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model.

Tanaka R, Goshima F, Esaki S, Sato Y, Murata T, Nishiyama Y, Watanabe D, Kimura H.

Am J Cancer Res. 2017 Aug 1;7(8):1693-1703. eCollection 2017.

11.

Differential Day-Night Outcome to HSV-2 Cutaneous Infection.

Matsuzawa T, Nakamura Y, Ogawa Y, Ishimaru K, Goshima F, Shimada S, Nakao A, Kawamura T.

J Invest Dermatol. 2018 Jan;138(1):233-236. doi: 10.1016/j.jid.2017.07.838. Epub 2017 Aug 24. No abstract available.

12.

The Epstein-Barr Virus BRRF1 Gene Is Dispensable for Viral Replication in HEK293 cells and Transformation.

Yoshida M, Watanabe T, Narita Y, Sato Y, Goshima F, Kimura H, Murata T.

Sci Rep. 2017 Jul 20;7(1):6044. doi: 10.1038/s41598-017-06413-7.

13.

Elimination of LMP1-expressing cells from a monolayer of gastric cancer AGS cells.

Sato Y, Ochiai S, Murata T, Kanda T, Goshima F, Kimura H.

Oncotarget. 2017 Jun 13;8(24):39345-39355. doi: 10.18632/oncotarget.16996.

14.

The C-Terminus of Epstein-Barr Virus BRRF2 Is Required for its Proper Localization and Efficient Virus Production.

Watanabe T, Sakaida K, Yoshida M, Masud HMAA, Sato Y, Goshima F, Kimura H, Murata T.

Front Microbiol. 2017 Jan 31;8:125. doi: 10.3389/fmicb.2017.00125. eCollection 2017.

15.

Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.

Ando S, Kawada JI, Watanabe T, Suzuki M, Sato Y, Torii Y, Asai M, Goshima F, Murata T, Shimizu N, Ito Y, Kimura H.

Oncotarget. 2016 Nov 22;7(47):76793-76805. doi: 10.18632/oncotarget.12529.

16.

The Alarmin IL-33 Derived from HSV-2-Infected Keratinocytes Triggers Mast Cell-Mediated Antiviral Innate Immunity.

Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, Moriishi K, Nakao A, Shimada S.

J Invest Dermatol. 2016 Jun;136(6):1290-1292. doi: 10.1016/j.jid.2016.01.030. Epub 2016 Feb 9. No abstract available.

17.

Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor.

Murata T, Noda C, Narita Y, Watanabe T, Yoshida M, Ashio K, Sato Y, Goshima F, Kanda T, Yoshiyama H, Tsurumi T, Kimura H.

J Virol. 2016 Mar 28;90(8):3873-3889. doi: 10.1128/JVI.03227-15. Print 2016 Apr.

18.

The Epstein-Barr Virus BDLF4 Gene Is Required for Efficient Expression of Viral Late Lytic Genes.

Watanabe T, Narita Y, Yoshida M, Sato Y, Goshima F, Kimura H, Murata T.

J Virol. 2015 Oct;89(19):10120-4. doi: 10.1128/JVI.01604-15. Epub 2015 Jul 22.

19.

The Epstein-Barr virus BRRF2 gene product is involved in viral progeny production.

Watanabe T, Tsuruoka M, Narita Y, Katsuya R, Goshima F, Kimura H, Murata T.

Virology. 2015 Oct;484:33-40. doi: 10.1016/j.virol.2015.05.010. Epub 2015 Jun 5.

20.

Roles of Epstein-Barr virus BGLF3.5 gene and two upstream open reading frames in lytic viral replication in HEK293 cells.

Watanabe T, Fuse K, Takano T, Narita Y, Goshima F, Kimura H, Murata T.

Virology. 2015 Sep;483:44-53. doi: 10.1016/j.virol.2015.04.007. Epub 2015 May 15.

21.

The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas.

Suzuki M, Takeda T, Nakagawa H, Iwata S, Watanabe T, Siddiquey MN, Goshima F, Murata T, Kawada J, Ito Y, Kojima S, Kimura H.

Front Microbiol. 2015 Apr 9;6:280. doi: 10.3389/fmicb.2015.00280. eCollection 2015.

22.

Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.

Kanazawa T, Hiramatsu Y, Iwata S, Siddiquey M, Sato Y, Suzuki M, Ito Y, Goshima F, Murata T, Kimura H.

Clin Cancer Res. 2014 Oct 1;20(19):5075-84. doi: 10.1158/1078-0432.CCR-14-0580. Epub 2014 Aug 12.

23.

Role of latent membrane protein 1 in chronic active Epstein-Barr virus infection-derived T/NK-cell proliferation.

Ito T, Kawazu H, Murata T, Iwata S, Arakawa S, Sato Y, Kuzushima K, Goshima F, Kimura H.

Cancer Med. 2014 Aug;3(4):787-95. doi: 10.1002/cam4.256. Epub 2014 May 3.

24.

Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.

Siddiquey MN, Nakagawa H, Iwata S, Kanazawa T, Suzuki M, Imadome K, Fujiwara S, Goshima F, Murata T, Kimura H.

Cancer Sci. 2014 Jun;105(6):713-22. doi: 10.1111/cas.12418. Epub 2014 May 13.

25.

Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.

Goshima F, Esaki S, Luo C, Kamakura M, Kimura H, Nishiyama Y.

Int J Cancer. 2014 Jun 15;134(12):2865-77. doi: 10.1002/ijc.28631. Epub 2013 Dec 2.

26.

Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma.

Murata T, Iwata S, Siddiquey MN, Kanazawa T, Goshima F, Kawashima D, Kimura H, Tsurumi T.

PLoS One. 2013 May 3;8(5):e63566. doi: 10.1371/journal.pone.0063566. Print 2013.

27.

Mast cells play a key role in host defense against herpes simplex virus infection through TNF-α and IL-6 production.

Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, Nakao A, Moriishi K, Nishiyama Y, Shimada S.

J Invest Dermatol. 2013 Sep;133(9):2170-9. doi: 10.1038/jid.2013.150. Epub 2013 Mar 25.

28.

Generation and Characterization of UL21-Null Herpes Simplex Virus Type 1.

Muto Y, Goshima F, Ushijima Y, Kimura H, Nishiyama Y.

Front Microbiol. 2012 Nov 16;3:394. doi: 10.3389/fmicb.2012.00394. eCollection 2012.

29.

Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models.

Esaki S, Goshima F, Kimura H, Murakami S, Nishiyama Y.

Int J Cancer. 2013 Apr 1;132(7):1592-601. doi: 10.1002/ijc.27823. Epub 2012 Sep 26.

30.

Diabetic mice show an aggravated course of herpes-simplex virus-induced facial nerve paralysis.

Esaki S, Yamano K, Kiguchi J, Katsumi S, Keceli S, Okamoto H, Goshima F, Kimura H, Nishiyama Y, Murakami S.

Otol Neurotol. 2012 Oct;33(8):1452-7. doi: 10.1097/MAO.0b013e318268d54d.

PMID:
22931869
31.

Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant, HF10, protects mice from genital disease caused by herpes simplex virus type 2.

Luo C, Goshima F, Kamakura M, Mutoh Y, Iwata S, Kimura H, Nishiyama Y.

Front Microbiol. 2012 Apr 30;3:158. doi: 10.3389/fmicb.2012.00158. eCollection 2012.

32.
33.

Replication of Epstein-Barr virus primary infection in human tonsil tissue explants.

Gotoh K, Ito Y, Maruo S, Takada K, Mizuno T, Teranishi M, Nakata S, Nakashima T, Iwata S, Goshima F, Nakamura S, Kimura H.

PLoS One. 2011;6(10):e25490. doi: 10.1371/journal.pone.0025490. Epub 2011 Oct 5.

34.
35.

Hepatocyte growth factor incorporated into herpes simplex virus vector accelerates facial nerve regeneration after crush injury.

Esaki S, Kitoh J, Katsumi S, Goshima F, Kimura H, Safwat M, Yamano K, Watanabe N, Nonoguchi N, Nakamura T, Coffin RS, Miyatake SI, Nishiyama Y, Murakami S.

Gene Ther. 2011 Nov;18(11):1063-9. doi: 10.1038/gt.2011.57. Epub 2011 May 12.

PMID:
21562589
36.

Auditory and vestibular defects induced by experimental labyrinthitis following herpes simplex virus in mice.

Esaki S, Goshima F, Kimura H, Ikeda S, Katsumi S, Kabaya K, Watanabe N, Hashiba M, Nishiyama Y, Murakami S.

Acta Otolaryngol. 2011 Jul;131(7):684-91. doi: 10.3109/00016489.2010.546808. Epub 2011 Apr 28.

PMID:
21526906
37.

Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer.

Fujiwara S, Nawa A, Luo C, Kamakura M, Goshima F, Kondo C, Kiyono T, Kikkawa F, Nishiyama Y.

Cancer Gene Ther. 2011 Feb;18(2):77-86. doi: 10.1038/cgt.2010.53. Epub 2010 Oct 1.

38.

Herpes simplex virus UL56 interacts with and regulates the Nedd4-family ubiquitin ligase Itch.

Ushijima Y, Luo C, Kamakura M, Goshima F, Kimura H, Nishiyama Y.

Virol J. 2010 Aug 3;7:179. doi: 10.1186/1743-422X-7-179.

39.

Apoptosis induction after herpes simplex virus infection differs according to cell type in vivo.

Esaki S, Goshima F, Katsumi S, Watanabe D, Ozaki N, Murakami S, Nishiyama Y.

Arch Virol. 2010 Aug;155(8):1235-45. doi: 10.1007/s00705-010-0712-2. Epub 2010 Jun 11.

PMID:
20535504
40.

Herpes simplex virus type 2 tegument protein UL56 relocalizes ubiquitin ligase Nedd4 and has a role in transport and/or release of virions.

Ushijima Y, Goshima F, Kimura H, Nishiyama Y.

Virol J. 2009 Oct 16;6:168. doi: 10.1186/1743-422X-6-168.

41.

Protective role of Fas-FasL signaling in lethal infection with herpes simplex virus type 2 in mice.

Ishikawa T, Yamada H, Oyamada A, Goshima F, Nishiyama Y, Yoshikai Y.

J Virol. 2009 Nov;83(22):11777-83. doi: 10.1128/JVI.01006-09. Epub 2009 Sep 9.

42.

Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.

Ishida D, Nawa A, Tanino T, Goshima F, Luo CH, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Tsurumi T, Nishiyama Y, Kikkawa F.

Cancer Lett. 2010 Feb 1;288(1):17-27. doi: 10.1016/j.canlet.2009.06.014. Epub 2009 Jul 14.

PMID:
19604626
43.

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.

Nawa A, Luo C, Zhang L, Ushjima Y, Ishida D, Kamakura M, Fujimoto Y, Goshima F, Kikkawa F, Nishiyama Y.

Curr Gene Ther. 2008 Jun;8(3):208-21. Review.

PMID:
18537595
44.

Microarray analysis of transcriptional responses to infection by herpes simplex virus types 1 and 2 and their US3-deficient mutants.

Kamakura M, Nawa A, Ushijima Y, Goshima F, Kawaguchi Y, Kikkawa F, Nishiyama Y.

Microbes Infect. 2008 Apr;10(4):405-13. doi: 10.1016/j.micinf.2007.12.019. Epub 2008 Jan 9.

PMID:
18403238
45.

Herpes simplex virus type 2 UL56 interacts with the ubiquitin ligase Nedd4 and increases its ubiquitination.

Ushijima Y, Koshizuka T, Goshima F, Kimura H, Nishiyama Y.

J Virol. 2008 Jun;82(11):5220-33. doi: 10.1128/JVI.02515-07. Epub 2008 Mar 19.

46.

Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.

Watanabe D, Goshima F, Mori I, Tamada Y, Matsumoto Y, Nishiyama Y.

J Dermatol Sci. 2008 Jun;50(3):185-96. doi: 10.1016/j.jdermsci.2007.12.001. Epub 2008 Jan 15.

PMID:
18226503
47.

[Oncolytic virotherapy using replication-competent herpes simplex viruses].

Nishiyama Y, Goshima F.

Uirusu. 2007 Jun;57(1):57-65. Review. Japanese.

48.

A regulatory role of interleukin 15 in wound healing and mucosal infection in mice.

Kagimoto Y, Yamada H, Ishikawa T, Maeda N, Goshima F, Nishiyama Y, Furue M, Yoshikai Y.

J Leukoc Biol. 2008 Jan;83(1):165-72. Epub 2007 Sep 28.

PMID:
17906118
49.

Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.

Kohno SI, Luo C, Nawa A, Fujimoto Y, Watanabe D, Goshima F, Tsurumi T, Nishiyama Y.

Cancer Gene Ther. 2007 Nov;14(11):918-26. Epub 2007 Aug 10.

PMID:
17693992
50.

Replication-competent, oncolytic herpes simplex virus type 1 mutants induce a bystander effect following ganciclovir treatment.

Luo C, Mori I, Goshima F, Ushijima Y, Nawa A, Kimura H, Nishiyama Y.

J Gene Med. 2007 Oct;9(10):875-83.

PMID:
17685493

Supplemental Content

Loading ...
Support Center